Opinion|Videos|July 16, 2026

Differentiating Revumenib and Ziftomenib: Label vs Perception

Pharmacists compare revumenib and ziftomenib in AML—QTc thresholds, CYP3A4 interactions, acid suppression limits, and differentiation syndrome monitoring to optimize safety.

In this episode, Zepcan compares the actual label data side by side, addressing agent complexity and monitoring requirements. She examines QTc monitoring, CYP3A4 interactions, PPI interactions, and pharmacokinetic profiles to help guide pharmacy practice.

Latest CME